AprilBio Approaching KOSDAQ Listing: "We Will Achieve Independent New Drug Development"

Demand Forecast on 13-14, Subscription on 19-20, Listing on 28
Expected Public Offering Price 20,000~23,000 Won

April Bio Online Corporate Presentation.

[Asia Economy Reporter Lee Gwan-joo] AprilBio, which is preparing for a KOSDAQ listing, held an online IPO press conference on the 13th to announce its growth plans and vision after listing.

Founded in 2013, AprilBio is a protein (antibody) therapeutic development company targeting autoimmune diseases, inflammatory diseases, and cancer by utilizing the platform technology 'SAFA (Anti-Serum Albumin Fab)' that extends the half-life of drugs and the 'antibody library (HuDVFab, Human naive Fab antibody library)' technology that discovers antibodies matching target antigens.

AprilBio is creating various long-acting new drug candidates and bispecific antibodies with global competitiveness by leveraging these two platform technologies. Last year, it successfully licensed its SAFA platform-based pipeline 'APB-A1' to the Danish global pharmaceutical company Lundbeck for approximately 540 billion KRW (excluding royalties). Currently, APB-A1 is undergoing Phase 1 clinical trials by the U.S. Food and Drug Administration (FDA), with plans to expand subsequent indications. Additionally, it is preparing for the second technology transfer of the inflammatory disease treatment 'APB-R3,' aiming to sign a contract within this year.

AprilBio is offering a total of 1.62 million shares in this public offering. The expected offering price is between 20,000 and 23,000 KRW per share, with a total offering amount of 32.4 billion to 37.3 billion KRW. The demand forecast will be conducted from the 13th to the 14th, followed by subscription from the 19th to the 20th, and the company is scheduled to enter the KOSDAQ market on the 28th. NH Investment & Securities is the lead underwriter for the listing.

AprilBio plans to invest the funds secured through this listing into research and development (R&D) to accelerate the research speed of new drug candidates and shorten development time. CEO Cha Sang-hoon stated, "We will strive to continuously generate stable profits and increase the company's value after listing by utilizing our globally competitive antibody and long-acting protein platform technologies. Our goal is to license out about one new drug candidate per year and achieve independent new drug development to grow into a global biotech company."

This content was produced with the assistance of AI translation services.